Specific targeting of a mutant, activated egf receptor found in glioblastoma using a monoclonal antibody

A truncated epidermal growth factor receptor (EGFR) expressed from a rearranged and amplified EGFR gene is present at high frequency in gliomas. In this work we show that when this receptor is expressed in NIH3T3 fibroblasts it is partially activated and confers tumorigenicity to this cell line in vivo but no growth advantage in vitro anchorage‐independent growth assays. Because the mutation occurs in the extracellular domain of the receptor, it can be considered to represent a glioma‐specific tumour marker. Here we demonstrate that 2 monoclonal antibodies, DH 1.1 and DH8.3, raised to a synthetic peptide spanning the unique junctional sequence, can recognise the mutant receptor but not the normal receptor in both denatured and native states. Furthermore, radiolabelled antibody DH8.3 successfully targets tumours expressing this antigen in nude mice.

[1]  J. Park,et al.  Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. , 1994, Cancer research.

[2]  J. Delattre,et al.  Oncogene amplification in human gliomas: a molecular cytogenetic analysis. , 1994, Oncogene.

[3]  W. Gullick,et al.  A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines. , 1994, British Journal of Cancer.

[4]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  V. P. Collins,et al.  Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. , 1994, Oncogene.

[6]  R. Perez-soler,et al.  Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Burger,et al.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. , 1994, Cancer research.

[8]  D. Bigner,et al.  Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.

[9]  P. Humphrey,et al.  Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas , 1993, Journal of Neuroimmunology.

[10]  J. Kemshead,et al.  Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. , 1993, British Journal of Cancer.

[11]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Yoshimoto,et al.  Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. , 1992, Oncogene.

[13]  S. Larson,et al.  Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. , 1991, Journal of the National Cancer Institute.

[14]  W. Gullick,et al.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.

[15]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Shibuya,et al.  A Deletion Mutation within the Ligand Binding Domain Is Responsible for Activation of Epidermal Growth Factor Receptor Gene in Human Brain Tumors , 1990, Japanese journal of cancer research : Gann.

[17]  P. Humphrey,et al.  Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Partanen,et al.  Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase , 1990, Journal of cellular biochemistry.

[19]  M. Hung,et al.  Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. , 1989, Oncogene.

[20]  P. Humphrey,et al.  Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. , 1988, Cancer research.

[21]  M. Mariani,et al.  Immunogenicity of a free synthetic peptide: carrier-conjugation enhances antibody affinity for the native protein. , 1987, Molecular immunology.

[22]  J. Downward,et al.  Antibodies to the autophosphorylation sites of the epidermal growth factor receptor protein‐tyrosine kinase as probes of structure and function. , 1985, The EMBO journal.

[23]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.